Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3549492 in Chinese Participants With Type 2 Diabetes
NCT07073170Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2025
- Primary completion
- Jan 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of naperiglipron in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Serious Adverse Events. Started Jul 2025; status: completed.
02
Drugs
naperiglipron
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07073170.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07073170.